News

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the Company and its partners will present three abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 – June 7, 2022 in Chicago.

06/01/2022

Here's Why Rafael Holdings Is Plummeting Today

A clinical trial failure with the company's lead candidate has investors running for the exits.

10/28/2021

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Rafael Holdings, Inc. (RFL) a buy, sell, or hold?

Rafael Holdings, Inc. (RFL) can hold. Click on Rating Page for detail.

What is Rafael Holdings, Inc.'s stock price?

The price of Rafael Holdings, Inc. (RFL) is 1.73 and it was updated on 2024-04-29 09:00:55.

Is Rafael Holdings, Inc. (RFL) overvalued or undervalued?

Currently Rafael Holdings, Inc. (RFL) is in undervalued.

News

From:

To:

News
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation into the Fairness of the Merger of Rafael Holdings, Inc. with Rafael Pharmaceuticals, Inc. New York, New York--(Newsfile Corp. - October 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rafael Holdings, Inc. ("Rafael Holdings" or the "Company") (NYSE: RFL) stock prior to August 16, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Rafael Holdings with Rafael Pharmaceuticals, Inc. U Mon, Oct. 18, 2021
Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08 NEWARK, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), announced that today it made a grant to Dr. Mary Margaret Huizinga of options to purchase 122,341 shares of Class B common stock of the Company with an exercise price equal to $30.54, the closing price of the Class B common stock on October 15, 2021, the trading day prior to the grant. Mon, Oct. 18, 2021
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business Update We expect Rafael Pharmaceuticals to report top line data from its AVENGER 500 Phase 3 registrational clinical trial in metastatic pancreatic cancer this calendar year Mon, Oct. 18, 2021
Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer NEWARK, N.J., Oct. 6, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., announced today the appointment of Mary Margaret (Mimi) Huizinga, MD, MPH as Chief Development and Medical Officer, effective October 18, 2021. Wed, Oct. 06, 2021
Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif. CRANBURY, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced that the Phase 1 clinical trial of CPI-613® (devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma is open for enrollment. The clinical trial will begin enrolling patients at City of Hope in Duarte, California, with other sites across the country to quickly follow. Mon, Sep. 27, 2021

SEC Filings

SEC Filings
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 04/08/2024
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 03/25/2024
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 03/14/2024
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 03/14/2024
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 03/13/2024
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 02/01/2024
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 01/18/2024
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 01/16/2024
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 01/12/2024
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 01/08/2024
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 12/26/2023
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 12/14/2023
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 12/14/2023
Rafael Holdings, Inc. (RFL) - DEFR14A SEC Filings 11/20/2023
Rafael Holdings, Inc. (RFL) - DEF 14A SEC Filings 11/20/2023
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 10/30/2023
Rafael Holdings, Inc. (RFL) - 10-K - Current report SEC Filings 10/30/2023
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 10/26/2023
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 10/26/2023
Rafael Holdings, Inc. (RFL) - SC 13D/A SEC Filings 10/24/2023
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 10/23/2023
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 09/26/2023
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 09/22/2023
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 08/30/2023
Rafael Holdings, Inc. (RFL) - S-8 SEC Filings 08/29/2023
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 08/09/2023
Rafael Holdings, Inc. (RFL) - SC 13D/A SEC Filings 08/07/2023
Rafael Holdings, Inc. (RFL) - SC 13D/A SEC Filings 08/03/2023
Rafael Holdings, Inc. (RFL) - 8-K/A - Current report SEC Filings 08/02/2023
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 08/02/2023
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 08/02/2023
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 08/01/2023
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 06/22/2023
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 06/13/2023
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 06/13/2023
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 06/05/2023
Rafael Holdings, Inc. (RFL) - SC 13D SEC Filings 05/11/2023
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 05/08/2023
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 04/04/2023
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 03/23/2023
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 03/14/2023
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 03/14/2023
Rafael Holdings, Inc. (RFL) - SC 13D/A SEC Filings 02/28/2023
Rafael Holdings, Inc. (RFL) - SC 13G/A SEC Filings 02/14/2023
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 02/02/2023
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 01/30/2023
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 01/26/2023
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 01/05/2023
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 01/05/2023
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 12/23/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 12/13/2022
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 12/13/2022
Rafael Holdings, Inc. (RFL) - DEF 14A SEC Filings 11/28/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 11/15/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 10/31/2022
Rafael Holdings, Inc. (RFL) - 10-K - Current report SEC Filings 10/31/2022
Rafael Holdings, Inc. (RFL) - 8-K/A - Current report SEC Filings 08/26/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 08/23/2022
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 08/09/2022
Rafael Holdings, Inc. (RFL) - 8-K/A - Current report SEC Filings 08/01/2022
Rafael Holdings, Inc. (RFL) - SC 13D SEC Filings 07/18/2022
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 07/18/2022
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 07/07/2022
Rafael Holdings, Inc. (RFL) - 8-K/A - Current report SEC Filings 07/06/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 07/01/2022
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 06/16/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 06/14/2022
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 06/14/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 05/31/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 05/09/2022
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 04/12/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 03/17/2022
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 03/17/2022
Rafael Holdings, Inc. (RFL) - EFFECT SEC Filings 03/08/2022
Rafael Holdings, Inc. (RFL) - EFFECT SEC Filings 03/08/2022
Rafael Holdings, Inc. (RFL) - CORRESP SEC Filings 03/03/2022
Rafael Holdings, Inc. (RFL) - S-3/A SEC Filings 03/02/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 02/28/2022
Rafael Holdings, Inc. (RFL) - 10-Q/A - Quarterly Report SEC Filings 02/28/2022
Rafael Holdings, Inc. (RFL) - RW SEC Filings 02/24/2022
Rafael Holdings, Inc. (RFL) - UPLOAD SEC Filings 02/22/2022
Rafael Holdings, Inc. (RFL) - S-3 SEC Filings 02/15/2022
Rafael Holdings, Inc. (RFL) - SC 13G/A SEC Filings 02/14/2022
Rafael Holdings, Inc. (RFL) - SC 13G/A SEC Filings 02/08/2022
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 02/03/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 02/02/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 01/21/2022
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 01/21/2022
Rafael Holdings, Inc. (RFL) - S-8 SEC Filings 01/19/2022
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 01/05/2022
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 12/15/2021
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 12/15/2021
Rafael Holdings, Inc. (RFL) - DEF 14A SEC Filings 11/24/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 11/22/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 10/28/2021
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 10/19/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 10/18/2021
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 10/18/2021
Rafael Holdings, Inc. (RFL) - 10-K - Current report SEC Filings 10/18/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 10/05/2021
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 09/28/2021
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 09/28/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 09/24/2021
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 09/24/2021
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 09/20/2021
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 09/17/2021
Rafael Holdings, Inc. (RFL) - S-4 SEC Filings 09/14/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 09/14/2021
Rafael Holdings, Inc. (RFL) - SC 13G SEC Filings 08/30/2021
Rafael Holdings, Inc. (RFL) - D SEC Filings 08/26/2021
Rafael Holdings, Inc. (RFL) - D SEC Filings 08/25/2021
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 08/25/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 08/24/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 08/10/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 07/15/2021
Rafael Holdings, Inc. (RFL) - 8-K/A - Current report SEC Filings 07/14/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 07/09/2021
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 06/22/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 06/21/2021
Rafael Holdings, Inc. (RFL) - EFFECT SEC Filings 06/18/2021
Rafael Holdings, Inc. (RFL) - EFFECT SEC Filings 06/17/2021
Rafael Holdings, Inc. (RFL) - CORRESP SEC Filings 06/16/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 06/14/2021
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 06/14/2021
Rafael Holdings, Inc. (RFL) - UPLOAD SEC Filings 06/10/2021
Rafael Holdings, Inc. (RFL) - EFFECT SEC Filings 06/08/2021
Rafael Holdings, Inc. (RFL) - EFFECT SEC Filings 06/07/2021
Rafael Holdings, Inc. (RFL) - S-3 SEC Filings 06/07/2021
Rafael Holdings, Inc. (RFL) - CORRESP SEC Filings 06/03/2021
Rafael Holdings, Inc. (RFL) - UPLOAD SEC Filings 06/02/2021
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 05/28/2021
Rafael Holdings, Inc. (RFL) - S-3 SEC Filings 05/27/2021
Rafael Holdings, Inc. (RFL) - S-8 SEC Filings 05/26/2021
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 05/10/2021
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 04/19/2021
Rafael Holdings, Inc. (RFL) - S-8 SEC Filings 04/14/2021
Rafael Holdings, Inc. (RFL) - EFFECT SEC Filings 03/24/2021
Rafael Holdings, Inc. (RFL) - EFFECT SEC Filings 03/23/2021
Rafael Holdings, Inc. (RFL) - CORRESP SEC Filings 03/19/2021
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 03/18/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 03/17/2021
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 03/17/2021
Rafael Holdings, Inc. (RFL) - S-3/A SEC Filings 03/11/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 03/11/2021
Rafael Holdings, Inc. (RFL) - UPLOAD SEC Filings 03/04/2021
Rafael Holdings, Inc. (RFL) - S-3 SEC Filings 02/24/2021
Rafael Holdings, Inc. (RFL) - SC 13G/A SEC Filings 02/12/2021
Rafael Holdings, Inc. (RFL) - RW SEC Filings 02/08/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 01/28/2021
Rafael Holdings, Inc. (RFL) - S-3 SEC Filings 01/20/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 01/19/2021
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 01/14/2021
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 01/07/2021
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 12/15/2020
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 12/15/2020
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 12/11/2020
Rafael Holdings, Inc. (RFL) - DEF 14A SEC Filings 11/23/2020
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 10/29/2020
Rafael Holdings, Inc. (RFL) - 10-K - Current report SEC Filings 10/29/2020
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 09/25/2020
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 09/01/2020
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 06/09/2020
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 06/09/2020
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 04/22/2020
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 04/07/2020
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 04/06/2020
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 03/26/2020
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 03/05/2020
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 03/05/2020
Rafael Holdings, Inc. (RFL) - SC 13G/A SEC Filings 02/12/2020
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 02/04/2020
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 01/28/2020
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 01/21/2020
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 01/06/2020
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 12/10/2019
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 12/09/2019
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 12/09/2019
Rafael Holdings, Inc. (RFL) - 25 SEC Filings 12/02/2019
Rafael Holdings, Inc. (RFL) - DEF 14A SEC Filings 11/21/2019
Rafael Holdings, Inc. (RFL) - CERT SEC Filings 11/18/2019
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 11/18/2019
Rafael Holdings, Inc. (RFL) - 8-A12B SEC Filings 11/18/2019
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 10/04/2019
Rafael Holdings, Inc. (RFL) - 10-K - Current report SEC Filings 10/04/2019
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 09/26/2019
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 09/24/2019
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 08/08/2019
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 08/08/2019
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 07/25/2019
Rafael Holdings, Inc. (RFL) - 8-K/A - Current report SEC Filings 07/22/2019
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 07/18/2019
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 06/05/2019
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 06/05/2019
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 03/12/2019
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 03/12/2019
Rafael Holdings, Inc. (RFL) - SC 13G SEC Filings 02/08/2019
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 01/28/2019
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 01/23/2019
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 01/18/2019
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 01/14/2019
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 01/10/2019
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 01/07/2019
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 12/10/2018
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 12/10/2018
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 12/06/2018
Rafael Holdings, Inc. (RFL) - DEF 14A SEC Filings 11/27/2018
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 11/21/2018
Rafael Holdings, Inc. (RFL) - PRE 14A SEC Filings 11/15/2018
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 11/09/2018
Rafael Holdings, Inc. (RFL) - 10-K/A - Current report SEC Filings 10/17/2018
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 10/15/2018
Rafael Holdings, Inc. (RFL) - 10-K - Current report SEC Filings 10/15/2018
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 09/27/2018
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 09/14/2018
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 09/07/2018
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 07/20/2018
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 06/11/2018
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 06/11/2018
Rafael Holdings, Inc. (RFL) - S-8 SEC Filings 05/22/2018
Rafael Holdings, Inc. (RFL) - 8-K - Current report SEC Filings 05/01/2018
Rafael Holdings, Inc. (RFL) - SC 13D SEC Filings 04/12/2018
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 03/29/2018
Rafael Holdings, Inc. (RFL) - 4 SEC Filings 03/28/2018
Rafael Holdings, Inc. (RFL) - 8-A12B/A SEC Filings 03/27/2018
Rafael Holdings, Inc. (RFL) - 10-12G/A SEC Filings 03/26/2018
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 03/14/2018
Rafael Holdings, Inc. (RFL) - 10-Q - Quarterly Report SEC Filings 03/12/2018
Rafael Holdings, Inc. (RFL) - CERT SEC Filings 03/05/2018
Rafael Holdings, Inc. (RFL) - 8-A12B SEC Filings 03/05/2018
Rafael Holdings, Inc. (RFL) - UPLOAD SEC Filings 03/01/2018
Rafael Holdings, Inc. (RFL) - CORRESP SEC Filings 02/20/2018
Rafael Holdings, Inc. (RFL) - 10-12G/A SEC Filings 02/20/2018
Rafael Holdings, Inc. (RFL) - UPLOAD SEC Filings 02/16/2018
Rafael Holdings, Inc. (RFL) - CORRESP SEC Filings 02/01/2018
Rafael Holdings, Inc. (RFL) - 10-12G/A SEC Filings 02/01/2018
Rafael Holdings, Inc. (RFL) - UPLOAD SEC Filings 01/19/2018
Rafael Holdings, Inc. (RFL) - 3 SEC Filings 01/03/2018
Rafael Holdings, Inc. (RFL) - CORRESP SEC Filings 12/26/2017
Rafael Holdings, Inc. (RFL) - 10-12G/A SEC Filings 12/26/2017
Rafael Holdings, Inc. (RFL) - UPLOAD SEC Filings 11/28/2017
Rafael Holdings, Inc. (RFL) - 10-12G SEC Filings 10/31/2017

Press Releases

StockPrice Release
Rafael holdings reports second quarter fiscal 2024 financial results 03/13/2024
Rafael holdings reports first quarter fiscal 2024 financial results 12/14/2023
Rafael holdings reports fourth quarter and full year fiscal 2023 financial results 10/30/2023
Cyclo therapeutics announces closing of $5.0 million private placement with rafael holdings, inc. 08/02/2023
Rafael holdings reports third quarter fiscal 2023 financial results and provides business update 06/13/2023
Rafael holdings reports first quarter fiscal 2023 financial results 12/13/2022
Rafael holdings reports fourth quarter fiscal 2022 financial results 10/31/2022
Cornerstone pharmaceuticals initiates phase 1 trial of cpi-613® (devimistat) in combination with chemoradiation for the treatment of advanced pancreatic cancer 09/28/2022
Rafael holdings sells its building located at 520 broad street in newark, new jersey and associated 800-car public garage 08/23/2022
Cornerstone pharmaceuticals strengthens scientific advisory board with the appointment of distinguished scholar jason locasale, ph.d. 07/06/2022
Cornerstone pharmaceuticals announces published data on cpi-613® (devimistat) as an effective approach to targeting carcinoma catabolism – update 06/16/2022
Cornerstone pharmaceuticals announces published data on cpi-613® (devimistat) as an effective approach to targeting carcinoma catabolism 06/16/2022
Rafael holdings reports third quarter fiscal 2022 financial results 06/14/2022
Cornerstone pharmaceuticals to present pancreatic cancer, clear cell sarcoma and biliary tract cancer research featuring cpi-613® (devimistat) at the 2022 american society of clinical oncology (asco) annual meeting 06/01/2022
European medicines agency grants orphan drug designation to cornerstone pharmaceuticals' cpi-613® (devimistat) for treatment of patients with advanced unresectable biliary tract cancer 05/24/2022
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of rafael holdings, inc. - rfl 03/26/2022
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of rafael holdings, inc. - rfl 03/23/2022
Rafael holdings reports second quarter fiscal 2022 financial results 03/17/2022
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of rafael holdings, inc. - rfl 03/16/2022
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of rafael holdings, inc. - rfl 03/14/2022
The law offices of frank r. cruz continues its investigation of rafael holdings, inc. (rfl) on behalf of investors 03/11/2022
Glancy prongay & murray llp, a leading securities fraud law firm, continues its investigation of rafael holdings, inc. (rfl) on behalf of investors 03/10/2022
Investor alert: law offices of howard g. smith continues its investigation of rafael holdings, inc. (rfl) on behalf of investors 03/09/2022
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of rafael holdings, inc. - rfl 03/09/2022
Glancy prongay & murray llp, a leading securities fraud law firm, announces investigation of rafael holdings, inc. (rfl) on behalf of investors 03/07/2022
The law offices of frank r. cruz announces investigation of rafael holdings, inc. (rfl) on behalf of investors 03/07/2022
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of rafael holdings, inc. - rfl 03/02/2022
William “bill” conkling to assume the role of chief executive officer as of february 1, 2022 01/21/2022
Rafael pharmaceuticals announces ongoing successful enrollment and opening of additional sites for phase 2 clinical trial of cpi-613® (devimistat) in combination with gemcitabine and cisplatin in patients with biliary tract cancer 01/18/2022
Rafael pharmaceuticals announces successful completion of dose escalation with no dose-limiting toxicity (dlt) in first cohort of apollo 613 phase 1/2 clinical trial of cpi-613® (devimistat) in patients with relapsed clear cell sarcoma 01/06/2022
Rafael holdings reports first quarter fiscal 2022 financial and operating results 12/15/2021
Rafael pharmaceuticals announces published data on cpi-613® (devimistat) from phase 2 clinical trial for refractory burkitt lymphoma at the 2021 american society of hematology (ash) annual meeting and exposition 12/13/2021
Rafael holdings realigns leadership team to support earlier stage pipeline focus 11/22/2021
Rafael pharmaceuticals announces first patient enrolled in apollo 613 phase 1/2 clinical trial of cpi-613® (devimistat) in patients with relapsed clear cell sarcoma 11/11/2021
European medicines agency grants orphan drug designation to rafael pharmaceuticals' cpi-613® (devimistat) for treatment of patients with relapsed or refractory burkitt's lymphoma 11/03/2021
Shareholder alert: levi & korsinsky, llp reminds investors of an investigation into the fairness of the merger of rafael holdings, inc. with rafael pharmaceuticals, inc. 10/18/2021
Rafael holdings announces inducement grant under nyse rule 303a.08 10/18/2021
Rafael holdings reports fourth quarter and full year fiscal 2021 financial and operating results and provides business update 10/18/2021
Rafael holdings appoints mimi huizinga, md, mph as chief development and medical officer 10/06/2021
Rafael pharmaceuticals announces apollo613 phase i/ii clinical trial of cpi-613® (devimistat) in combination with hydroxychloroquine in patients with relapsed clear cell sarcoma begins enrollment at city of hope in duarte, calif. 09/27/2021
Rafael holdings continues to expand its management team with a highly experienced global biopharmaceutical executive to build a fully integrated cancer metabolism therapeutics company and announces inducement grant under nyse rule 303a.08 09/24/2021
Rafael holdings announces inducement grant under nyse rule 303a.08 09/17/2021
Rafael holdings appoints patrick fabbio as chief financial officer 09/14/2021
Shareholder alert: levi & korsinsky, llp notifies investors of an investigation into the fairness of the merger of rafael holdings, inc. with rafael pharmaceuticals, inc. 08/26/2021
President and ceo of rafael pharmaceuticals, sanjeev luther, to present at the 11th annual world orphan drug congress usa 2021 08/26/2021
Rafael pharmaceuticals announces the successful completion of phase 1b clinical trial and initiates phase 2 for cpi-613® (devimistat) in combination with gemcitabine and cisplatin in patients with biliary tract cancer 08/25/2021
Rafael holdings announces closing of $104.2 million private placement 08/24/2021
Rafael holdings announces $104.2 million private placement 08/20/2021
Rafael holdings expands leadership team with three highly experienced global biopharmaceutical executives to build a fully integrated cancer metabolism therapeutics company 08/17/2021
Rafael (rfl) stockholder alert - andrews & springer llc is seeking more cash for shareholders of rafael holdings, inc. 08/16/2021
Rafael pharmaceuticals announces positive preplanned interim futility analysis of pivotal phase 3 trial (armada 2000) of cpi-613® (devimistat) for relapsed or refractory acute myeloid leukemia (aml) 07/01/2021
Rafael pharmaceuticals to present pancreatic & biliary tract cancer data on cpi-613® (devimistat) from its multicenter, randomized phase 1b/2 trials at the 2021 european society of medical oncology world gastrointestinal (gi) congress 06/30/2021
Fda grants rafael pharmaceuticals orphan drug designation for cpi-613® (devimistat) for treatment of biliary cancer 06/29/2021
Stockholder alert: kaskela law llc announces investigation of rafael holdings, inc. and encourages stockholders to contact the firm - rfl 06/28/2021
Rafael holdings investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates rafael holdings, inc. - rfl 06/24/2021
Rafael holdings and rafael pharmaceuticals management presented at the raymond james 2021 human health innovation conference on june 22, 2021 06/23/2021
Rafael holdings merger investigation: halper sadeh llp announces investigation into whether the merger of rafael holdings, inc. is fair to shareholders; investors are encouraged to contact the firm – rfl 06/21/2021
Rafael holdings announces strategic merger with rafael pharmaceuticals to form a focused late-stage clinical oncology company 06/21/2021
Rafael holdings appoints three highly experienced biopharmaceutical leaders to its board of directors 06/14/2021
Rafael holdings announces inducement grant under nyse rule 303a.08 05/28/2021
Rafael pharmaceuticals to present new pancreatic cancer and biliary tract cancer data featuring cpi-613® (devimistat) at the american society of clinical oncology (asco) 2021 virtual scientific program 05/26/2021
Rafael holdings announces inducement grant under nyse rule 303a.08 04/16/2021
Rafael pharmaceuticals crosses enrollment of 150 patients in pivotal phase 3 trial (armada 2000) of cpi-613® (devimistat) for relapsed or refractory acute myeloid leukemia (aml) 03/30/2021
Rafael holdings reports second quarter fiscal year 2021 results 03/17/2021
Rafael holdings enhances senior management team with additions of ameet mallik, ceo and william conkling, cco 03/11/2021
Rafael pharmaceuticals to present at b. riley securities virtual oncology investor conference 01/19/2021
Rafael pharmaceuticals to present at 39th annual j.p. morgan healthcare conference 01/13/2021
Rafael holdings reports first quarter fiscal year 2021 results 12/15/2020
Update - rafael pharmaceuticals receives fda fast track designation for cpi-613® (devimistat) for the treatment of acute myeloid leukemia (aml) 12/15/2020
Rafael pharmaceuticals receives fda fast track designation for cpi-613® (devimistat) for the treatment of acute myeloid leukemia (aml) 12/15/2020
Rafael pharmaceuticals partners with sara's cure and sarc for the launch of phase 2 clinical trial for cpi-613® (devimistat) in combination with hydroxychloroquine for patients with clear cell sarcoma of soft tissue 12/01/2020
Rafael pharmaceuticals partners with sara's cure and sarc for the launch of phase 2 clinical trial for cpi-613® (devimistat) in combination with hydroxychloroquine for patients with clear cell sarcoma of soft 12/01/2020
Rafael pharmaceuticals receives fda fast track designation for cpi-613® (devimistat) for the treatment of pancreatic cancer 11/10/2020
Fda grants rafael pharmaceuticals orphan drug designation for cpi-613® (devimistat) for treatment of soft tissue sarcoma 10/29/2020
Rafael holdings reports q3 loss per share of $0.14 06/09/2020
Rafael holdings reports q2 loss per share of $0.08 03/05/2020
Rafael holdings q1 loss per share $0.10 12/09/2019
Rafael pharmaceuticals - phase 2 clinical trial of cpi-613 will begin enrolling patients at massachusetts general hospital starting december 12/02/2019
Rafael pharma says 100 patients enrolled in pivotal phase 3 trial of cpi-613 10/08/2019
Rafael holdings reports q4 loss per share of $0.16 10/03/2019
Rafael holdings, inc. reports earnings results for the full year ended july 31, 2019 10/02/2019
Rafael holdings, inc. adopts second amended and restated by-laws 09/25/2019

More Headlines

News
Rafael Holdings Continues to Expand its Management Team with a Highly Experienced Global Biopharmaceutical Executive to Build a Fully Integrated Cancer Metabolism Therapeutics Company and Announces Inducement Grant Under NYSE Rule 303A.08 NEWARK, N.J., Sept. 24, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., announced today the appointment of Ashok Marin, Chief Legal Officer. 09/24/2021
Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08 NEWARK, N.J., Sept. 17, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., announced today it made a grant to Patrick Fabbio of options to purchase 105,602 shares of Class B common stock of the Company with an exercise price equal to $36.32, the closing price of the Class B common stock on September 16, 2021, the trading day prior to the grant. 09/17/2021
Rafael Holdings Appoints Patrick Fabbio as Chief Financial Officer NEWARK, N.J., Sept. 14, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., announced today the appointment of Patrick Fabbio as Chief Financial Officer. 09/14/2021
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Rafael Holdings, Inc. with Rafael Pharmaceuticals, Inc. New York, New York--(Newsfile Corp. - August 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rafael Holdings, Inc. ("Rafael Holdings" or the "Company") (NYSE: RFL) stock prior to August 16, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Rafael Holdings with Rafael Pharmaceuticals, Inc. Unde 08/26/2021
Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer CRANBURY, N.J., Aug. 25, 2021 (GLOBE NEWSWIRE) -- -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the successful completion of a Phase 1b clinical trial of CPI-613® (devimistat) in combination with gemcitabine and cisplatin in patients with biliary tract cancer. In collaboration with Michigan Medicine , the Phase 1b study consisted of a multicenter trial of gemcitabine and cisplatin with devimistat as first-line therapy for patients with locally advanced unresectable or metastatic biliary tract cancer who have had no prior treatment. “We are extremely excited and gratified to have completed Phase 1b and to be able to advance to the next phase (Phase 2),” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “Advanced biliary tract cancer is a rare and aggressive cancer with a 5-year survival rate of less than 5%, and the continuation of the trial aligns with our mission to help patients with significant unmet medical needs.” 08/25/2021
Rafael Holdings Announces Closing of $104.2 Million Private Placement NEWARK, N.J., Aug. 24, 2021 /PRNewswire/ -- Rafael Holdings, Inc. (NYSE: RFL) today announced the closing of the previously announced private investment in public equity (PIPE) financing. 08/24/2021
Rafael Holdings Announces $104.2 Million Private Placement NEWARK, N.J., Aug. 20, 2021 /PRNewswire/ -- Rafael Holdings, Inc. (NYSE: RFL) today announced that it has entered into definitive agreements to sell securities in a private placement that is expected to result in gross proceeds to the company of $104.2 million, before deducting placement agent and other offering expenses. 08/20/2021
Rafael Holdings Expands Leadership Team with Three Highly Experienced Global Biopharmaceutical Executives to Build a Fully Integrated Cancer Metabolism Therapeutics Company NEWARK, N.J., Aug. 17, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical company focused on developing novel cancer metabolism therapeutics, today announced the appointment of three senior biopharmaceutical leaders to its executive management team: Gus Kodersha, Chief Technical Operations Officer; Melissa Lozner, Chief Compliance & Ethics Officer; and Brandi Robinson, Chief Corporate Affairs Officer. 08/17/2021
RAFAEL (RFL) STOCKHOLDER ALERT - Andrews & Springer LLC Is Seeking More Cash for Shareholders of Rafael Holdings, Inc. WILMINGTON, Del.--(BUSINESS WIRE)--Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Rafael Holdings, Inc. (NYSE: RFL) (“Rafael Holdings” or the “Company”) relating to the merger of the Company with Rafael Pharmaceuticals, Inc. (“Rafael Pharmaceuticals”), a privately-held company. The two parties have announced that they reached an a 08/16/2021
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer Company reaches important milestone to advance potential novel therapy for this subset of gastrointestinal cancers Company reaches important milestone to advance potential novel therapy for this subset of gastrointestinal cancers 06/29/2021
STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Rafael Holdings, Inc. and Encourages Stockholders to Contact the Firm - RFL Philadelphia, Pennsylvania--(Newsfile Corp. - June 28, 2021) - Kaskela Law LLC announces that it is investigating Rafael Holdings, Inc. ("Rafael Holdings") (NYSE: RFL) on behalf of the company's stockholders.On June 21, 2021, Rafael Holdings announced that it had entered into an agreement to acquire Rafael Pharmaceuticals, Inc. ("Pharmaceuticals") in an all-stock transaction. According to the announcement, Pharmaceuticals' stockholders will receive shares of Rafael Holdings' common stock "amounting to approximately 48% of the currently... 06/28/2021
RAFAEL HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Rafael Holdings, Inc. - RFL NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Rafael Pharmaceuticals, Inc. (“Pharma”) to Rafael Holdings, Inc., (“the Company”) (NYSE: RFL). Under the terms of the proposed transaction, Pharma shareholders will receive Holdings Class B common stock amounting to approximately 48% of the currently outstanding capitalization of the company. Additional equity 06/24/2021
Rafael Holdings and Rafael Pharmaceuticals Management Presented at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021 NEWARK, N.J. and CRANBURY N.J. 06/23/2021
Rafael Holdings Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Rafael Holdings, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – RFL NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Rafael Holdings, Inc. (“Holdings”) (NYSE: RFL) and Rafael Pharmaceuticals, Inc. (“Pharma”) is fair to Holdings shareholders. In connection with the proposed merger, Pharma shareholders will receive Holdings Class B common stock amounting to approximately 48% of the currently outstanding capitalization of the company. Additional equity in the company is expected to be issued in 06/21/2021
Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology Company NEWARK, N.J. and CRANBURY, N.J. 06/21/2021
Rafael Holdings Appoints Three Highly Experienced Biopharmaceutical Leaders to its Board of Directors NEWARK, N.J., June 14, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical company focused on developing novel cancer metabolism therapeutics, today announced the appointment of three senior biopharmaceutical leaders to its Board of Directors: Ameet Mallik, Chief Executive Officer of Rafael Holdings; Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., (NASDAQ GS: MRNA); and Mark McCamish, M.D. 06/14/2021
Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08 NEWARK, N.J., May 28, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), today announced that, on May 27, 2021, it made a grant to Ameet Mallik, Rafael Holdings' Chief Executive Officer, of 908,497 restricted shares of the Company's Class B common stock in accordance with Mr. 05/28/2021
Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08 NEWARK, N.J., April 16, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), today announced that on April 15, 2021 it made a grant to William Conkling of options to purchase 118,409 shares of Class B common stock of the Company with an exercise price equal to $40.85, the closing price of the Class B common stock on April 14, 2021, the trading day prior to the grant. 04/16/2021
Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results NEWARK, N.J., March 17, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.0 million and a loss per share of $0.50 for the second quarter of its 2021 fiscal year, the three months ended January 31, 2021. 03/17/2021
Rafael Holdings Enhances Senior Management Team with Additions of Ameet Mallik, CEO and William Conkling, CCO NEWARK, N.J., March 11, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), today announced that its Board of Directors has recruited Ameet Mallik to become the company's Chief Executive Officer, succeeding its founder, Howard Jonas. 03/11/2021
Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial launches, FDA-granted Fast Track designations and other recent accomplishments on Wednesday, Jan. 20 President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial launches, FDA-granted Fast Track designations and other recent accomplishments on Wednesday, Jan. 20 01/19/2021
Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference, on Thursday, Jan. 14. 01/13/2021
UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML) CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's lead compound, CPI-613® (devimistat), for the treatment of acute myeloid leukemia (AML). 12/15/2020
Rafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it will initiate a Phase 2 clinical trial of CPI-613®(devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue. In partnership with Sara's Cure and Sarcoma Alliance for Research through Collaboration (SARC) , Rafael will begin enrolling patients into the Simon two-stage design trial at sites across the United States. 12/01/2020
Rafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it will initiate a Phase 2 clinical trial of CPI-613® (devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue. In partnership with Sara's Cure and Sarcoma Alliance for Research through Collaboration (SARC), Rafael will begin enrolling patients into the Simon two-stage design trial at sites across the United States. 12/01/2020
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer CRANBURY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's lead compound, CPI-613® (devimistat), for the treatment of metastatic pancreatic cancer. 11/10/2020
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma Company to launch clinical trial in clear cell sarcoma, a subtype of soft tissue sarcoma, in the coming months Company to launch clinical trial in clear cell sarcoma, a subtype of soft tissue sarcoma, in the coming months 10/29/2020

Unlock

RFL Ratings Summary

RFL Quant Ranking